{"title":"Ferroptosis in hematological malignancies: molecular mechanisms and therapeutic potential.","authors":"Jiaxi Liu, Rui Liu, Jiyu Miao, Aili He","doi":"10.1007/s13402-025-01142-w","DOIUrl":null,"url":null,"abstract":"<p><p>Ferroptosis, an iron-dependent form of regulated cell death characterized by overwhelming accumulation of lipid peroxidation, has emerged as a prominent area of interest in cancer research. Its underlying mechanisms are complex, and the high heterogeneity of hematologic malignancies adds additional challenges. Unlike solid cancers, hematologic malignancies lack fixed tissue architecture and exist within the dynamic bone marrow microenvironment, where iron metabolism, redox balance, and lipid remodeling are uniquely regulated. These differences create distinct metabolic vulnerabilities-particularly in iron and polyunsaturated fatty acid metabolism-that may render hematologic cancer cells more sensitive to ferroptotic stress. Given these unique features, a systematic understanding of ferroptosis in hematologic malignancies is critical for both elucidating disease mechanisms and exploring novel therapeutic strategies. This review summarizes the current understanding of ferroptosis in the pathogenesis and therapeutic resistance of hematologic malignancies, highlighting its mechanistic diversity across leukemia, lymphoma, and multiple myeloma. We also discuss emerging therapeutic strategies that exploit ferroptosis and outline key challenges and future directions for translating ferroptosis-based interventions into clinical practice.</p>","PeriodicalId":9690,"journal":{"name":"Cellular Oncology","volume":"49 1","pages":"10"},"PeriodicalIF":4.8000,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12748143/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cellular Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13402-025-01142-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Ferroptosis, an iron-dependent form of regulated cell death characterized by overwhelming accumulation of lipid peroxidation, has emerged as a prominent area of interest in cancer research. Its underlying mechanisms are complex, and the high heterogeneity of hematologic malignancies adds additional challenges. Unlike solid cancers, hematologic malignancies lack fixed tissue architecture and exist within the dynamic bone marrow microenvironment, where iron metabolism, redox balance, and lipid remodeling are uniquely regulated. These differences create distinct metabolic vulnerabilities-particularly in iron and polyunsaturated fatty acid metabolism-that may render hematologic cancer cells more sensitive to ferroptotic stress. Given these unique features, a systematic understanding of ferroptosis in hematologic malignancies is critical for both elucidating disease mechanisms and exploring novel therapeutic strategies. This review summarizes the current understanding of ferroptosis in the pathogenesis and therapeutic resistance of hematologic malignancies, highlighting its mechanistic diversity across leukemia, lymphoma, and multiple myeloma. We also discuss emerging therapeutic strategies that exploit ferroptosis and outline key challenges and future directions for translating ferroptosis-based interventions into clinical practice.
Cellular OncologyBiochemistry, Genetics and Molecular Biology-Cancer Research
CiteScore
10.40
自引率
1.50%
发文量
0
审稿时长
16 weeks
期刊介绍:
The Official Journal of the International Society for Cellular Oncology
Focuses on translational research
Addresses the conversion of cell biology to clinical applications
Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions.
A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. To this end Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients.
In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations.